New combinations and immunotherapies for melanoma: latest evidence and clinical utility

by Menzies, Alexander M., Long, Georgina V.
Published 2013

Dabrafenib and its potential for the treatment of metastatic melanoma

by Menzies, Alexander M, Long, Georgina V, Murali, Rajmohan
Published 2012

Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care

by Scolyer, Richard A., Long, Georgina V., Thompson, John F.
Published in Mol Oncol (2011)

Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas

by Silva, Inês Pires da, Batten, Marcel, Long, Georgina V.
Published in Br J Cancer (2018)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma

by Wilmott, James S., Scolyer, Richard A., Long, Georgina V., Hersey, Peter
Published 2012

Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion

by Menzies, Alexander M, Yeh, Iwei, Botton, Thomas, Bastian, Boris C., Scolyer, Richard A, Long, Georgina V
Published in Pigment Cell Melanoma Res (2015)

Targeting NK Cells to Enhance Melanoma Response to Immunotherapies

by Lee, Hansol, Da Silva, Inês Pires, Palendira, Umaimainthan, Scolyer, Richard A., Long, Georgina V., Wilmott, James S.
Published in Cancers (Basel) (2021)

Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors

by Muir, Christopher Alan, Menzies, Alexander M, Clifton-Bligh, Roderick John, Long, Georgina V, Scolyer, Richard A, Tsang, Venessa
Published in J Endocr Soc (2021)

Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report

by Hultin, Sebastian, Nahar, Kazi, Menzies, Alexander M., Long, Georgina V., Fernando, Suran L., Atkinson, Victoria, Cebon, Jonathan, Wong, Muh Geot
Published in BMC Nephrol (2020)

Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition

by Park, John J., Diefenbach, Russell J., Byrne, Natalie, Long, Georgina V., Scolyer, Richard A., Gray, Elin S., Carlino, Matteo S., Rizos, Helen
Published in Cancers (Basel) (2021)

Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors

by Ziemys, Arturas, Kim, Michelle, Menzies, Alexander M., Wilmott, James S., Long, Georgina V., Scolyer, Richard A., Kwong, Larry, Holder, Ashley, Boland, Genevieve
Published in Front Oncol (2020)

Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma

by Menzies, Alexander M., Haydu, Lauren E., Carlino, Matteo S., Azer, Mary W. F., Carr, Peter J. A., Kefford, Richard F., Long, Georgina V.
Published 2014

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series

by Carlino, Matteo S, Vanella, Vito, Girgis, Christina, Giannarelli, Diana, Guminski, Alex, Festino, Lucia, Kefford, Richard F, Menzies, Alexander M, Long, Georgina V, Ascierto, Paolo A
Published in Br J Cancer (2016)

Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling

by Chien, Andy J., Haydu, Lauren E., Biechele, Travis L., Kulikauskas, Rima M., Rizos, Helen, Kefford, Richard F., Scolyer, Richard A., Moon, Randall T., Long, Georgina V.
Published 2014

BRAF inhibition decreases cellular glucose uptake in melanoma in association with reduction in cell volume

by Theodosakis, Nicholas, Held, Matthew A., Marzuka-Alcala, Alexander, Meeth, Katrina M., Micevic, Goran, Long, Georgina V., Scolyer, Richard A., Stern, David F., Bosenberg, Marcus W.
Published in Mol Cancer Ther (2015)

Response to Letter to the Editor: “Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes”

by Tsang, Venessa H M, McGrath, Rachel T, Clifton-Bligh, Roderick J, Scolyer, Richard A, Jakrot, Valerie, Guminski, Alexander D, Long, Georgina V, Menzies, Alexander M
Published in J Clin Endocrinol Metab (2020)

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma

by Carlino, Matteo S., Todd, Jason R., Gowrishankar, Kavitha, Mijatov, Branka, Pupo, Gulietta M., Fung, Carina, Snoyman, Stephanie, Hersey, Peter, Long, Georgina V., Kefford, Richard F., Rizos, Helen
Published in Mol Oncol (2014)

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies

by Lee, Jenny H., Long, Georgina V., Menzies, Alexander M., Lo, Serigne, Guminski, Alexander, Whitbourne, Kataraina, Peranec, Michelle, Scolyer, Richard, Kefford, Richard F., Rizos, Helen, Carlino, Matteo S.
Published in JAMA Oncol (2018)

Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis

by Krisp, Christoph, Parker, Robert, Pascovici, Dana, Hayward, Nicholas K., Wilmott, James S., Thompson, John F., Mann, Graham J., Long, Georgina V., Scolyer, Richard A., Molloy, Mark P.
Published in Br J Cancer (2018)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab

by Nahar, Kazi J, Rawson, Robert V, Ahmed, Tasnia, Tattersall, Stephen, Sandanayake, Neomal, Kiely, Christopher J, Lo, Serigne, Carlino, Matteo, Palendira, Umaimainthan, Scolyer, Richard A, Long, Georgina V, Menzies, Alexander M
Published in J Immunother Cancer (2020)